Indeed, when loss of ZEB1 expression was stratified with CD133 expression (Fig. 5a, hazard ratio 1.73, 0.95% CI, 1.28–2.34; **P = 0.0003) the result was shortened patient survival, suggesting that the effect of ZEB1 loss on survival was consistent with an increase in the proportion of the glioma stem cell population in the tumor. Here, ZEB1 is linked to central nervous system cancer.